Anixa Biosciences Reports No Revenue for Fiscal Year Ending October 31, 2025

Anixa Biosciences, Inc. reported no revenue for the fiscal year ending October 31, 2025, maintaining a trend from the previous year. The company has not yet generated income from its therapeutics or vaccine programs, which are still in development. Anixa's accumulated deficit reached approximately $251.7 million, with a net loss of about $11 million for the year. The company’s cash, cash equivalents, and short-term investments totaled approximately $15.2 million at the end of the fiscal year, down from $19.9 million in 2024. The decrease in cash was attributed to ongoing operational expenses, including research and development costs, which totaled approximately $5.1 million, a reduction from $6.4 million in the prior year.

In terms of operational developments, Anixa has made significant strides in its clinical programs. The company is advancing its CAR-T therapy, lira-cel, for ovarian cancer, with ongoing Phase 1 clinical trials at the H. Lee Moffitt Cancer Center. The trials have shown promising results, with patients tolerating the treatment well and some exhibiting signs of efficacy. Additionally, Anixa is developing a breast cancer vaccine in collaboration with the Cleveland Clinic, which has also entered clinical trials. The company has expanded its vaccine discovery program to explore additional cancer types, including lung, colon, and prostate cancers.

Anixa's research and development expenses reflect its focus on these clinical programs, with costs associated with the breast cancer vaccine and CAR-T therapy decreasing due to fluctuations in manufacturing activities. General and administrative expenses also saw a decline, primarily due to reduced costs in investor relations and stock option compensation. The company continues to rely on strategic collaborations to support its development efforts, which may help mitigate costs and enhance its operational capabilities.

Looking ahead, Anixa anticipates that its therapeutics and vaccine development will remain the primary focus of its operations. The company has indicated that it may seek additional funding through equity offerings or other financing methods to support its ongoing projects. However, it acknowledges the inherent risks associated with early-stage biotechnology development, including the potential for delays in clinical trials and the challenges of securing regulatory approvals. Anixa's future revenue generation will depend on the successful completion of its clinical trials and the eventual licensing of its technologies to larger pharmaceutical companies.